Skip to main content
Medical information Clinical review pending

Genetic Testing

CYP2B6 Gene Efavirenz Poor Metabolism of Genetic Test

This genetic test assesses how your body metabolizes the HIV medication Efavirenz, helping to personalize treatment for better effectiveness and fewer side effects.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube) or Saliva sample. Confirm with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is required for this test. Confirm with the laboratory before booking.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the CYP2B6 Gene Efavirenz Poor Metabolism of Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Patients starting or currently on Efavirenz therapy for HIV.
  • ✓Individuals experiencing side effects potentially related to Efavirenz metabolism.
  • ✓Patients with treatment failure while on Efavirenz.
  • ✓Individuals with a family history suggesting altered drug metabolism.
02

In plain language

What this test helps you understand

This test helps predict how an individual will metabolize Efavirenz, guiding personalized dosing strategies to improve treatment outcomes and reduce adverse drug reactions associated with HIV therapy.
The CYP2B6 Gene Efavirenz Poor Metabolism Test uses Next Generation Sequencing (NGS) technology to analyze variations in the CYP2B6 gene. This gene plays a key role in breaking down the antiretroviral drug Efavirenz, commonly used in HIV treatment. Understanding your specific genetic makeup related to this gene is crucial for effective HIV management. The test identifies genetic variants that can affect how quickly or slowly your body processes Efavirenz. This information helps healthcare providers tailor medication dosages or choose alternative treatments to optimize drug efficacy and minimize potential side effects. This test is particularly relevant for individuals starting or currently on Efavirenz therapy.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is required for this test. Confirm with the laboratory before booking.
SampleBlood sample (EDTA tube) or Saliva sample. Confirm with the laboratory before booking.
MethodologyNext Generation Sequencing (NGS) is used to analyze the CYP2B6 gene for relevant genetic variants.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes specific known variants in the CYP2B6 gene. It does not detect all possible genetic variations that could affect Efavirenz metabolism. Other factors, such as liver function and concurrent medications, also influence drug metabolism. Results should be interpreted in the context of the patient's overall clinical picture.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The CYP2B6 gene provides instructions for making an enzyme that helps break down certain medications, including Efavirenz.
Knowing your CYP2B6 gene status helps predict how your body will process Efavirenz, allowing your doctor to adjust your treatment for better results and fewer side effects.
It means your body breaks down Efavirenz more slowly than average, which might require a different dosage or medication.
Results will indicate your metabolic status (e.g., normal, intermediate, poor metabolizer) based on the identified genetic variants. Your doctor will explain what this means for you.
This test is primarily indicated for individuals using or planning to use Efavirenz. Discuss with your doctor if it's relevant for your situation.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp